HC Wainwright reiterated their buy rating on shares of Addex Therapeutics (NASDAQ:ADXN – Free Report) in a report published on Wednesday morning, Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright also issued estimates for Addex Therapeutics’ FY2024 earnings at $0.49 EPS, Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.00 EPS and FY2025 earnings at ($0.28) EPS.
Addex Therapeutics Stock Performance
Shares of NASDAQ ADXN opened at $9.44 on Wednesday. Addex Therapeutics has a one year low of $5.00 and a one year high of $27.90. The firm has a market capitalization of $10.01 million, a P/E ratio of -0.55 and a beta of 1.79. The company’s fifty day moving average is $9.20 and its two-hundred day moving average is $10.56.
Addex Therapeutics (NASDAQ:ADXN – Get Free Report) last announced its quarterly earnings data on Monday, September 30th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($0.07) by ($1.70). Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.26 million. On average, sell-side analysts forecast that Addex Therapeutics will post -0.36 earnings per share for the current fiscal year.
Addex Therapeutics Company Profile
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Read More
- Five stocks we like better than Addex Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 9/30 – 10/4
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.